B-cell imaging with zirconium-89 labelled rituximab PET-CT at baseline is associated with therapeutic response 24  weeks after initiation of rituximab treatment in rheumatoid arthritis patients

B cells are key players in the pathogenesis of rheumatoid arthritis (RA). Although successful in 50 –60% of patients with RA, anti-B-cell therapy given as rituximab could be more efficient by identifying potent...

Source: Arthritis Research and Therapy - November 18, 2016 Category: Rheumatology Authors: Stefan Bruijnen, Michel Tsang-A-Sjoe, Hennie Raterman, Tamara Ramwadhdoebe, Dani ëlle Vugts, Guus van Dongen, Marc Huisman, Otto Hoekstra, Paul-Peter Tak, Alexandre Voskuyl and Conny van der Laken Source Type: research